Goldman Sachs Group upgraded shares of Zimmer Biomet (NYSE:ZBH) from a sell rating to a neutral rating in a research note published on Tuesday, December 19th, MarketBeat reports. Goldman Sachs Group currently has $125.00 price objective on the medical equipment provider’s stock.
Several other brokerages have also commented on ZBH. SunTrust Banks set a $136.00 price target on Zimmer Biomet and gave the company a buy rating in a research note on Wednesday, November 1st. Royal Bank of Canada cut their target price on Zimmer Biomet to $125.00 and set an outperform rating on the stock in a research note on Tuesday, November 7th. Morgan Stanley dropped their price target on Zimmer Biomet from $146.00 to $136.00 and set an overweight rating on the stock in a research note on Thursday, November 2nd. BMO Capital Markets dropped their price target on Zimmer Biomet from $140.00 to $135.00 and set an outperform rating on the stock in a research note on Thursday, November 2nd. Finally, Deutsche Bank upgraded Zimmer Biomet from a hold rating to a buy rating and set a $128.00 price target on the stock in a research note on Tuesday, November 14th. Two analysts have rated the stock with a sell rating, six have given a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $137.42.
Zimmer Biomet (ZBH) traded down $0.24 during mid-day trading on Tuesday, hitting $122.29. 1,261,700 shares of the company were exchanged, compared to its average volume of 1,467,710. The stock has a market capitalization of $24,760.00, a price-to-earnings ratio of 38.10, a PEG ratio of 1.96 and a beta of 1.15. Zimmer Biomet has a 1 year low of $108.03 and a 1 year high of $133.49. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47.
Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.74 by ($0.02). The business had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.83 billion. Zimmer Biomet had a return on equity of 3.82% and a net margin of 5.43%. The firm’s revenue for the quarter was down .8% compared to the same quarter last year. During the same quarter last year, the business posted $1.79 earnings per share. research analysts anticipate that Zimmer Biomet will post 8.03 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Monday, January 29th. Shareholders of record on Friday, December 29th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.79%. The ex-dividend date is Thursday, December 28th. Zimmer Biomet’s payout ratio is currently 29.91%.
Large investors have recently modified their holdings of the business. Private Advisor Group LLC lifted its stake in shares of Zimmer Biomet by 18.6% in the 3rd quarter. Private Advisor Group LLC now owns 6,733 shares of the medical equipment provider’s stock valued at $791,000 after purchasing an additional 1,057 shares during the last quarter. Ingalls & Snyder LLC lifted its stake in Zimmer Biomet by 2.6% during the 3rd quarter. Ingalls & Snyder LLC now owns 19,675 shares of the medical equipment provider’s stock worth $2,304,000 after acquiring an additional 507 shares in the last quarter. Koch Industries Inc. lifted its stake in Zimmer Biomet by 49,697.3% during the 2nd quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock worth $1,033,000 after acquiring an additional 1,038,674 shares in the last quarter. Jensen Investment Management Inc. lifted its stake in Zimmer Biomet by 24.2% during the 2nd quarter. Jensen Investment Management Inc. now owns 5,850 shares of the medical equipment provider’s stock worth $751,000 after acquiring an additional 1,140 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in Zimmer Biomet by 10.0% during the 3rd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 16,444 shares of the medical equipment provider’s stock worth $1,925,000 after acquiring an additional 1,494 shares in the last quarter. Institutional investors own 85.92% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/01/11/zimmer-biomet-zbh-upgraded-by-goldman-sachs-group-to-neutral.html.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.